Chris Mason

Oak Ridge National Laboratory — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

34h-index4.3kcitations140works1.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pluripotent Stem Cells Research(51), Biomedical Ethics and Regulation(43), 3D Printing in Biomedical Research(32), CRISPR and Genetic Engineering(22), Biomedical and Engineering Education(19)

Publications140 total

Multimedia and simulation enhancements to a nuclear security experience-based BattleBoard Culmination Exercise
The Journal of Defense Modeling and Simulation Applications Methodology Technology·2025
Applied Astrobiology: An Integrated Approach to the Future of Life in Space
Astrobiology·2025· 2 cited
DNA sequences encoding mammalian expression of Staphylococcal nuclease variants
Figshare·2025· 1 citedOpen Access
Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations
Molecular Therapy·2024· 5 citedOpen Access
An autonucleolytic suspension HEK293F host cell line for high-titer serum-free AAV5 and AAV9 production with reduced levels of DNA impurity
Molecular Therapy — Methods & Clinical Development·2024Open Access
The evolving realm of nucleic acids: past, present, and future
Nucleic Acid Insights·2024Open Access
Engineering an Autonucleolytic Mammalian Suspension Host Cell Line to Reduce DNA Impurity Levels in Serum-Free Lentiviral Process Streams
ACS Synthetic Biology·2024· 3 citedOpen Access
Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations
2023Open Access
IOCost: Block Input–Output Control for Containers in Datacenters
IEEE Micro·2023· 2 cited
DNA sequences encoding mammalian expression of Staphylococcal nuclease variants
Figshare·2023Open Access
Screening chimeric GAA variants in preclinical study results in hematopoietic stem cell gene therapy candidate vectors for Pompe disease
Molecular Therapy — Methods & Clinical Development·2022· 16 citedOpen Access
Abstract 62: Temporal concordance rates of pathogenic variants in liquid biopsies taken after solid tissue NGS profiling in a real-world pan-cancer cohort
Cancer Research·2022
High-throughput analysis of hematopoietic stem cell engraftment after intravenous and intracerebroventricular dosing
Molecular Therapy·2022· 13 citedOpen Access
IOCost: block IO control for containers in datacenters
2022· 18 citedOpen Access
High throughput monitoring of safety, potency and stability of gene therapy cell products in lysosomal disease patients
Molecular Genetics and Metabolism·2022
High-resolution cellular and molecular follow up of lysosomal disease patients treated with hematopoietic stem cell lentiviral gene therapy
Molecular Genetics and Metabolism·2022
Gene Therapy Developments for Pompe Disease
Biomedicines·2022· 48 citedOpen Access
Screening of Chimeric GAA Variants in a Preclinical Study of Pompe Disease Results in Candidate Vector for Hematopoietic Stem Cell Gene Therapy
2021· 2 citedOpen Access
Genetically engineered microglia-like cells have therapeutic potential for neurodegenerative disease
2021· 2 citedOpen Access
Engineering HEK293T cell lines to express nuclease for DNA clearance in lentiviral vector production
2021
page 1 of 7Next →

Frequent Co-authors

Emily J Culme-Seymour(7), Farlan Veraitch(6), David Brindley(5), Peter Dunnill(4), Natasha L. Davie(4), Ivan Wall(4), Elisa Manzotti(4), Martin Birchall(3), Andrew E. Pelling(3), Mike Hoare(3), Diana Hernandez(3), Ludmila Ruban(3), Edwin M. Horwitz(3), Leanne Partington(2), Mark W. Lowdell(2), Carol Pui‐Kei Chu(2), Michael A. Horton(2), Hae‐Won Kim(2), Gary J. Lye(2), Emma Stephenson(2)